Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy
Yu. A. Vasyuk, Yu. N. Belenkov(Sechenov University)
Cited by 80
Related Papers
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)
|European Journal of Heart Failure|2020|364
Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology
|European Journal of Heart Failure|2020|344
Cancer Diagnosis in Patients with Heart Failure: Epidemiology, Clinical Implications and Gaps in Knowledge
|European Journal of Heart Failure|2018|183